Vnitr Lek 2016, 62(1):57-61

Dangerous cucumbers - Leyll's syndrome

Ján Csomor1,*, Bohuš Bunganič1, Sergey Zakharov2, Igor Pafčuga3, Pavel Sedloň1, Petr Urbánek1
1 Interní klinika 1. LF UK a Ústřední vojenská nemocnice - Vojenská fakultní nemocnice Praha
2 Toxikologické informační středisko Kliniky pracovního lékařství 1. LF UK a VFN Praha
3 Klinika popáleninové medicíny 3. LF UK a FN Královské Vinohrady Praha

Leyll's syndrome (syndrome of toxic epidermal necrolysis) is a rare disease, firstly described by Scottish doctor of medicine Allan Lyell in 1956. It is characterized by huge skin and mucosa necrolysis, which affects at least 30 % of body surface, and systemic symptoms. According to the frequency of the occurrence it is an extremely rare condition, with an incidence of 0.5-2 cases per million residents per year. Leyll's syndrome is considered as a toxoallergic reaction, triggered mostly by some medication and it is associated with a very high mortality rate (in the literature reported between 30 to 90 %). Adequate and timely local and systemic treatment at the Intensive Care Unit or at the specialized clinic can improve the overall poor prognosis of the patients. In our case report we describe a very rare case of the Lyell's syndrome after exposure to the antifungal organosulfur compound, which is widely used by the homegardners and farmers.

Keywords: bis-dithiocarbamates; Leyll's syndrome; toxic epidermal necrolysis

Received: June 24, 2015; Accepted: September 23, 2015; Published: January 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Csomor J, Bunganič B, Zakharov S, Pafčuga I, Sedloň P, Urbánek P. Dangerous cucumbers - Leyll's syndrome. Vnitr Lek. 2016;62(1):57-61.
Download citation

References

  1. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011; 7(6): 803-813. Go to original source... Go to PubMed...
  2. Nešpor D, Lipový B, Gregorová N. Cyklosporin A v terapii toxické epidermální nekrolýzy. Dermatol praxi 2011; 5(3): 156-159.
  3. Cohen V, Stuart Bronze M (ed). Toxic Epidermal Necrolysis. Dostupné z WWW: <http://emedicine.medscape.com/article/229698-overview#showall>.
  4. Beneš J et al. Infekční lékařství. Galén: Praha 2009. ISBN 978-80-7262-644-1.
  5. Osthaus WA. Leyll-Syndrom. In: Haverkamp W, Herth F, Messmann H. Internistische Intensivmedizin: Methoden - Diagnose - Therapie. Thieme Georg Verlag: Stuttgart 2008. ISBN 978-3131406217.
  6. Bastuji-Garin S, Fouchard N, Bertocchi M et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115(2): 149-153. Go to original source... Go to PubMed...
  7. Babini G. A case of erythroderma caused by zinc dithiocarbamate. Arch Ital Dermatol Venereol Sessuol 1966; 34: 230-238. Go to PubMed...
  8. Piraccini BM, Cameli N, Peluso AM et al. A case of allergic contact dermatitis due to the pesticide maneb. Contact Dermatitis 1991; 24(5): 381. Go to original source... Go to PubMed...
  9. Ellender RP, Peters CW, Albritton HL et al. Clinical considerations for epidermal necrolysis. Oschner J 2014; 14(3): 413-417.
  10. Roujeau JC, Kelly JP, Naldi L et al. Medication Use and the Risk of Stevens-Johnsons Syndrome or Toxic Epidermal Necrolysis. N Engl J Med 1995; 333(24): 1600-1607. Go to original source... Go to PubMed...
  11. Napoli B, D'Arpa N, Masellis M. The Treatment of Lyell's Syndrome: our Experience. Ann Burns Fire Disasters 2006; 19(1): 33-35.
  12. Egan CA, Grant WJ, Morris SE et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999; 40(3): 458-461. Go to original source... Go to PubMed...
  13. Schneck J, Fagot JP, Sekula P et al. Effects of treatment on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58(1): 33-40. Go to original source... Go to PubMed...
  14. Lissia M, Mulas P, Bulla A et al. Toxic epidermal necrolysis (Lyell's disease). Burns 2010; 36(2): 152-163. Go to original source... Go to PubMed...
  15. Darlenski R, Kazandjieva J, Tsankov N. Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS. Clin Dermatol 2015; 33(5): 538-541. Go to original source... Go to PubMed...
  16. Hinc-Kasprzyk J, Polak-Krzemińska A, Ożóg-Zabolska I. Toxic epidermal necrolysis. Anaesthesiol Intensive Ther 2015; 47(3): 257-262. Go to original source... Go to PubMed...
  17. Paulmann M, Mockenhaupt M. Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges 2015; 13(7): 625-645. Go to original source... Go to PubMed...
  18. Sun J, Liu J, Gong QL et al. Stevens-Johnsons Syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People's Republic of China. Drug Des Devel Ther 2014; 8: 2539-2547. Dostupné z DOI: <http://dx.doi.org/10.2147/DDDT.S71736>. Go to original source... Go to PubMed...
  19. Vokurka J, Fassmann A, Zgažarová S et al. Stevens-Johnsonův syndrom a jeho projevy v ústní dutině. Prakt zub Lék 2010; 58(3): 39-44. Go to original source...
  20. Matějovič M. Lyellův syndrom. Anest Intenziv Med 2013; 24(1): 42.
  21. Šuca H, Tokarik M, Pafčuga I et al. Toxická epidermální nekrolýza - naše zkušenosti s celkovou i lokální léčbou. Hojení ran 2011; 5(2): 22-24.
  22. Lipový B, Říhová H, Gregorová N et al. Toxická epidermální nekrolýza: přehled možností terapie. Hojení ran 2011; 5(4): 6-12.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.